BONEFOS CAPSULE

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

CLODRONATE DISODIUM (CLODRONATE DISODIUM TETRAHYDRATE)

Prieinama:

BAYER INC

ATC kodas:

M05BA02

INN (Tarptautinis Pavadinimas):

CLODRONIC ACID

Dozė:

400MG

Vaisto forma:

CAPSULE

Sudėtis:

CLODRONATE DISODIUM (CLODRONATE DISODIUM TETRAHYDRATE) 400MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

120

Recepto tipas:

Prescription

Gydymo sritis:

BONE RESORPTION INHIBITORS

Produkto santrauka:

Active ingredient group (AIG) number: 0122982001; AHFS:

Autorizacija statusas:

CANCELLED POST MARKET

Leidimo data:

2018-03-27

Prekės savybės

_ _
_BONEFOS Product Monograph _
_Page 1 of 29_
PRODUCT MONOGRAPH
PR BONEFOS
®
Clodronate disodium for injection
60 mg/mL
for slow intravenous infusion only
and
Clodronate disodium capsules
400 mg/capsule
Bone metabolism regulator
(Antihypercalcemic agent)
Bayer Inc.
2920 Matheson Boulevard East,
Mississauga, Ontario
L4W 5R6
www.bayer.ca
Submission Control No. 200438
Date of Revision:
March 30, 2017
© 2017, Bayer Inc.
® TM see www.bayer.ca/tm-mc.
_ _
_BONEFOS Product Monograph _
_Page 2 of 29_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
............................................................13
STORAGE AND STABILITY
..........................................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................14
PART II: SCIENTIFIC INFORMATION
................................................................................16
PHARMACEUTICAL INFORMATION
..........................................................................1